Niacin: Chemical forms, bioavailability, and health effects

Nutrition Reviews

Volumn 70, Issue 6, 2012, Pages 357-366

  Mackay, Douglas ^a   Hathcock, John ^a   Guarneri, Erminia ^b  

^a International and Scientific Affairs   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

Adverse effects; Bioavailability; Inositol hexanicotinate; Niacin; Serum lipids

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSITOL NICOTINATE; ISOBUTYRIC ACID DERIVATIVE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM CHLOROPHENOXYISOBUTYRATE; MAGNESIUM DERIVATIVE; NICERITROL; NICOTINAMIDE; NICOTINIC ACID; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHEMICAL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DEPRESSION; DIET SUPPLEMENTATION; DIETARY INTAKE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEALTH CARE PERSONNEL; HEARTBURN; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INTERMITTENT CLAUDICATION; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIVER TOXICITY; NAUSEA; NIACIN FLUSH; NICOTINIC ACID DEFICIENCY; PELLAGRA; PEPTIC ULCER; PERIPHERAL VASCULAR DISEASE; PHARMACODYNAMICS; RAYNAUD PHENOMENON; RISK ASSESSMENT; STOICHIOMETRY; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; VITAMIN B3 DEFICIENCY; VITAMIN DEFICIENCY;

BIOLOGICAL AVAILABILITY; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; NIACIN;

EID: 84861697885     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2012.00479.x     Document Type: Article

References (64)

1. th ed. Philadelphia: Lippincott, Williams & Wilkins; 2006:442.
2. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press; 1998:123.
3. th anniversary review. J Intern Med. 2005;258:94-114.
4. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 1955;54:558-559.
5. Ganji SH, Zhang L-H, Kamanna VS, etal. Effect of niacin on lipoproteins and atherosclerosis. Future Lipidol. 2006;1:549-557.
6. Scientific Committee on Food. European Commission. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Levels of Nicotinic Acid and Nicotinamide (Niacin). SCF/CS/NUT/UPPLEV/39/Final. 2002:Available at:. Accessed 15 June 2011.
7. Expert Group on Vitamins and Minerals. Food Standards Agency. Safe Upper Levels for Vitamins and Minerals. 2003:Available at:. Accessed15 June 2011.
8. nd ed. Washington, DC: Council for Responsible Nutrition; 2004:85-91.
9. Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO). A Model for Establishing Upper Levels of Intake for Nutrients and Related Substances: report of a Joint FAO/WHO Technical Workshop on Food Nutrient Risk Assessment. 2006:Available at:. Accessed15 June 2011.
10. Bechgaard H, Jespersen S. GI absorption of niacin in humans. J Pharm Sci. 1977;66:871-872.
11. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med. 1992;92:77-81.
12. Sebrell WH, Butler RE. A reaction to the oral administration of nicotinic acid. JAMA. 1938;11:2286-2287.
13. Spies TD, Bean WB, Stone RE. The treatment of subclinical and classic pellagra. Use of nicotinic acid, nicotinic acid amide and sodium nicotinate, with special reference to the vasodilator action and the effect on mental symptoms. JAMA. 1938;11:584-592.
14. Norris RB. "Flush-free niacin": dietary supplement may be "benefit free. Prev Cardiol. 2006;9:64-65.
15. Aronov DM, Keenan JM, Akhmedzhanov NM, etal. Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia. Arch Fam Med. 1996;5:567-575.
16. Menon R, Tolbert D, Cefali E. The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet. Biopharm Drug Dispos. 2007;28:297-306.
17. European Food Safety Authority (EFSA). Inositol hexanicotinate (inositol hexaniacinate) as a source of niacin (vitamin B3) added for nutritional purposes in food supplements. Scientific Opinion of the Panel on Food Additives and Nutrient Sources Added to Food. EFSA J. 2009;949:1-20.
18. Harthon JG, Lindqvist JT. On the elimination of unabsorbed hexanicotinic acid esters of meso-inositol in the feces. Arzneimittelforschung. 1964;14:1170-1171.
19. Welsh AL, Ede M. Inositol hexanicotinate for improved nicotinic acid therapy. Preliminary report. Int Record Med. 1961;174:9-15.
20. Sommer H. Nicotinic acid level in the blood and fibrinolysis under the influence of hexanicotinate acid esters of m-inositol. Arzneimittelforschung. 1965;15:1337-1339.
21. Carlson LA, Oro L, Ostman J. Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. Acta Med Scand. 1968;183:457-465.
22. Harthon L, Brattsand R. Enzymatic hydrolysis of pentaerythritoltetranicotinate and meso-inositolhexanicotinate in blood and tissues. Arzneimittelforschung. 1979;29:1859-1862.
23. Kruse W, Kruse W, Raetzer H, etal. Nocturnal inhibition of lipolysis in man by nicotinic acid and derivatives. Eur J Clin Pharmacol. 1979;16:11-15.
24. Benjó AM, Maranhão RC, Coimbra SR, etal. Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. Atherosclerosis. 2006;187:116-122.
25. Meyers CD, Carr MC, Park S, etal. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med. 2003;139:996-1002.
26. Parsons WB Jr. Use of nicotinic acid compounds in the treatment of hyperlipidemia. In: Casdorph HR, ed. Treatment of the Hyperlipidemic States. Springfield, IL: Charles C. Thomas Press; 1971:336-374.
27. Fukuwatari T, Ebata M, Sasaki R, etal. Bioavailability of nicotinamide-rich powder obtained from bonito as niacin source in humans and rats [in Japanese]. J Home Econ. 2005;56:265-272.
28. Abourjaily HM. A review of Niaspan®, an extended-release niacin. Nutr Clin Care. 2001;4:250-255.
29. Duggal JK, Singh M, Attri N, etal. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2010;15:158-166.
30. Knopp RH, Ginsberg J, Albers JJ, etal. Contrasting effects of unmodified and time-release forms of naicin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642-650.
31. McKenney JM, Proctor JD, Harris S, etal. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271:672-677.
32. Shepherd J, Packard CJ, Patsch JR, etal. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979;63:858-867.
33. Wahlberg G, Walldius G, Olsson AG, etal. Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyperlipoproteinaemia. J Intern Med. 1990;228:151-157.
34. Gurakar A, Hoeg JM, Kostner G, etal. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985;57:293-301.
35. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
36. Knopp RH, Alagona P, Davidson M, etal. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47:1097-1104.
37. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998;82:29U-34U.
38. Vogt A, Kassner U, Hostalek U, etal. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin. 2006;22:417-425.
39. Keenan JM, Fontaine PL, Wenz JB, etal. Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991;151:1424-1432.
40. Holti G. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon. J Int Med Res. 1979;7:473-483.
41. O'Hara J. A double-blind placebo-controlled study of Hexopal in the treatment of intermittent claudication. J Int Med Res. 1985;13:322-327.
42. Ring EF, Porto LO, Bacon PA. Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome. J Int Med Res. 1981;9:393-400.
43. Sunderland GT, Belch JJ, Sturrock RD, etal. A double-blind randomised placebo-controlled trial of hexopal in primary Raynaud's disease. Clin Rheumatol. 1988;7:46-49.
44. Head KA. Inositol hexaniacinate: a safer alternative to niacin. Altern Med Rev. 1995;1:176-184.
45. Head KA. Inositol hexaniacinate. Altern Med Rev. 1998;3:222-223.
46. Agusti R, Jordan C, Aste H, Tapia F. Effects of hexanicotinate of meso-inositol in patients with primary hyperlipidemia [in Spanish]. Rev Invest Clin 1978;30:327-335.
47. Fischer M, Falkensammer C. New drug combination for medical management of hyperlipidemia: clinical study [in German]. Int J Clin Pharmacol Biopharm. 1977;15:585-589.
48. Koskinen P, Inkovaara J, Ala-Kaila K, etal. Effect of calcium p-chlorphenoxyisobutyrate and calcium carbonate on plasma lipids and lipoproteins of patients with hyperlipoproteinaemia. Ann Clin Res. 1977;9:335-341.
49. Ziliotto GR, Lamberti G, Wagner A, etal. Comparative studies of the response of normolipemic and dyslipidemic aged subjects to two forms of delayed-action nicotinic acid polyesters. Pentaerythrotol tetranicotinate and inositol hexanicotinate. Results of a controlled cross-over trial [in Italian]. Arch Sci Med (Torino). 1977;134:359-394.
50. Keenan J. Extended-release nicotinic acid versus inositol hexanicotinate for the treatment of dyslipidemia. J Clin Lipidol. 2010;4:216-217.
51. Head A. Treatment of intermittent claudication with inositol nicotinate. Practitioner. 1986;230:49-54.
52. O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. Br J Clin Pract. 1988;42:377-383.
53. Ring EF, Bacon PA. Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud's phenomena. J Int Med Res. 1977;5:217-222.
54. Genus Pharmaceuticals [package insert]. Hexopal 500mg tablets. eMC Website, updated 21 May 2008. Available at:. Accessed15 June 2011.
55. Beyer JL. Managing depression in geriatric populations. Ann Clin Psychiatry. 2007;19:221-238.
56. Capuzzi DM, Morgan JM, Brusco OA Jr, etal. Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep. 2000;2:64-71.
57. Clementz GL, Holmes AW. Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroenterol. 1987;9:582-584.
58. Knip M, Douek IF, Moore WP, etal. Safety of high-dose nicotinamide: a review. Diabetologia. 2000;43:1337-1345.
59. Hoffer A. Adverse effects of niacin in emergent psychosis. JAMA. 1969;207:1355.
60. Vague P, Vialettes B, Lassmann-Vague V, etal. Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet. 1987;329:619-620.
61. Mendola G, Casamitjana R, Gomis R. Effect of nicotinamide therapy upon B-cell function in newly diagnosed type-1 (insulin-dependent) diabetic patients. Diabetiologia. 1989;32:160-162.
62. Chase HP, Butler-Simon N, Garg S, etal. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:444-446.
63. Pozzilli P, Visalli N, Signore A, etal. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetiologia. 1995;38:848-852.
64. Lampeter EF, Klinghammer A, Scherbaum WA, etal. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes. 1998;47:980-984.